StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)

Close on Nov 18, 2026Market cap $99.30MP/E –Yield –

Outlook Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Outlook Therapeutics's revenue for the twelve months ending Sep 30, 2019 was $8.15M, up 163.8% year over year. For fiscal 2025 it was $1.41M, down 82.6% from the year before. The highest annual figure on record is $8.15M in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2025Sep 30, 2025$1.41M-82.6%
FY2019Sep 30, 2019$8.15M+163.8%
FY2018Sep 30, 2018$3.09M-19.0%
FY2017Sep 30, 2017$3.81M+27.9%
FY2016Sep 30, 2016$2.98M-42.9%
FY2015Sep 30, 2015$5.22M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2025CQ2 2025Jun 30, 2025$1.51M+41.0%
Q4 FY2019CQ3 2019Sep 30, 2019$5.85M+658.3%
Q3 FY2019CQ2 2019Jun 30, 2019$583.85K-24.4%
Q2 FY2019CQ1 2019Mar 31, 2019$641.14K-16.9%
Q1 FY2019CQ4 2018Dec 31, 2018$1.07M+38.3%
Q4 FY2018CQ3 2018Sep 30, 2018$771.89K-73.4%
Q3 FY2018CQ2 2018Jun 30, 2018$771.89K+154.6%
Q2 FY2018CQ1 2018Mar 31, 2018$771.89K+154.6%
Q1 FY2018CQ4 2017Dec 31, 2017$771.89K+154.6%
Q4 FY2017CQ3 2017Sep 30, 2017$2.90M+486.4%
Q3 FY2017CQ2 2017Jun 30, 2017$303.14K-38.7%
Q2 FY2017CQ1 2017Mar 31, 2017$303.14K-69.5%
Q1 FY2017CQ4 2016Dec 31, 2016$303.14K–
Q4 FY2016CQ3 2016Sep 30, 2016$494.89K–
Q3 FY2016CQ2 2016Jun 30, 2016$494.89K–
Q2 FY2016CQ1 2016Mar 31, 2016$994.89K–

More Outlook Therapeutics figures

See a number that looks wrong?